The effect of oxcarbazepine on behavioural despair and learned helplessness

European Journal of Pharmacology

Volumn 347, Issue 1, 1998, Pages 23-27

  Beijamini, Vanessa ^a   Skalisz, Luana L ^a   Joca, Samia R L ^a   Andreatini, Roberto ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Animal model; Depression; Forced swimming; Learned helplessness; Open field; Oxcarbazepine

Indexed keywords

OXCARBAZEPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; DRUG EFFECT; ENZYME INDUCTION; HELPLESSNESS; LEARNING; LOCOMOTION; MOTOR ACTIVITY; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; RAT; SWIMMING; TRANQUILIZING ACTIVITY;

ANIMALS; ANTICONVULSANTS; BEHAVIOR, ANIMAL; CARBAMAZEPINE; DEPRESSION; DISEASE MODELS, ANIMAL; HELPLESSNESS, LEARNED; MALE; MOTOR ACTIVITY; RATS; RATS, WISTAR;

EID: 0032540204     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00076-4     Document Type: Article

References (24)

1. Abel E.L., Bilitzke J. A possible alarm substance in the forced swimming test. Physiol. Behav. 48:1990;233-239.
2. Almeida R.N., Leite J.R. Effect of acute or chronic carbamazepine on experimentally-induced conflict in the rat. Psychopharmacology (Berlin). 100:1990;227-229.
3. Barros H.M.T., Leite J.R. Effects of acute and chronic carbamazepine administration on apomorphine-elicited stereotypy. Eur. J. Pharmacol. 123:1986;345-349.
4. Barros H.M.T., Leite J.R. The effects of carbamazepine on two animal models of depression. Psychopharmacology (Berlin). 92:1987;340-342.
5. Barros H.M.T., Braz S., Leite J.R. Effect of carbamazepine on dopamine release and reuptake in rat striatal slices. Epilepsia. 27:1986;534-537.
6. Borsini F., Meli A. Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology (Berlin). 94:1988;147-160.
7. Dilsaver S.C., Swann A.C., Chen Y.W., Shoaib A., Joe B., Krajewsky K., Gruber N., Tsai Y. Treatment of bipolar depression with carbamazepine: results of an open study. Biol. Psychiat. 40:1996;935-937.
8. Eidman D.S., Benedito M.A.C., Leite J.R. Daily changes in pentylenetetrazol-induced convulsions and open-field behaviour in rats. Physiol. Behav. 47(5):1990;853-856.
9. Emrich, H.M., 1990. Studies with oxcarbazepine (Trileptal®) in acute mania, in: Emrich, H., Schiwy, W., Silverstone, T. (Eds.), Carbamazepine and Oxcarbazepine in Psychiatry, CNS Publishers, London, pp. 83-88.
10. Emrich, H.M., 1994. Experience with oxcarbazepine in acute mania, in: Modigh, K., Robak, O.H., Vestergaard, P. (Eds.), Anticonvulsants in Psychiatry, Wrightson Biomedical Publishing, pp. 29-36.
11. Grant S.M., Faulds D. Oxcarbazepine: a review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. Drugs. 43:1992;873-888.
12. Kelly, A.E., 1993. Locomotor activity and exploration, in: Sahgal, A. (Ed.), Behavioural Neuroscience: A Practical Approach, Vol. II, Oxford Univ. Press, Oxford, pp. 1-21.
13. Maj J., Chojnacka-Wojcik E., Lewandowska A., Tatarczynska E., Wickzynska B. The central action of carbamazepine as a potential antidepressant drug. Pol. J. Pharmacol. Pharm. 37:1985;47-56.
14. Porsolt R.D., Anton G., Blavet N., Jalfre M. Behavioral despair in rats: a new model sensitive to antidepressant treatments. Eur. J. Pharmacol. 47:1978;379-391.
15. Post, R.M., 1987. Mechanism of action of carbamazepine and related anticonvulsants in affective illness. in: Meltzer, H. (Ed.), Psychopharmacology: The Third Generation of Progress, Raven Press, New York, pp. 567-576.
16. Post R.M., Uhde T.W., Wolff E.A. Profile of clinical efficacy and side-effects of carbamazepine in psychiatric illness: relationship to blood and CSF levels of carbamazepine and its 10,11-epoxide metabolite. Acta Psychiatr. Scand. 69:1984;104-120.
17. Post R.M., Ketter T.A., Denicoff K., Pazzaglia P.J., Leverich G.S., Marangell L.B., Callahan A.M., George M.S., Frye M.A. The place of anticonvulsant therapy in bipolar illness. Psychopharmacology (Berlin). 128:1996;115-129.
18. Sartori V.A., Andreatini R., Leite J.R. Anxiolytic effect of carbamazepine in experimentally-induced anxiety. J. Drug Dev. 5:1993;251-254.
19. Schwabe S. Oxcarbazepine: clinical development program. Epilepsia. 35(Suppl. 5):1994;S51-S53.
20. Sherman A.D., Sacquitine J.L., Petty F. Specificity of the learned helplessness model of depression. Pharmacol. Biochem. Behav. 16:1982;449-454.
21. Wildgrube, C., 1990. Case studies on prophylactic long-term effects of oxcarbazepine in recurrent affective disorders, in: Emrich, H., Schiwy, W., Silverstone, T. (Eds.), Carbamazepine and Oxcarbazepine in Psychiatry, CNS Publishers, London, pp. 89-94.
22. Willner P. The validity of animal models of depression. Psychopharmacology. 83:1984;1-16.
23. Willner, P., 1995. Dopaminergic mechanisms in depression and mania. In: Bloom, F.E., Kupfer, D.J. (Eds.), Psychopharmacology: The Fourth Generation of Progress, Raven Press, New York, pp. 921-931.
24. Zangrossi H., Leite J.R., Graeff F.G. Anxiolytic effect of carbamazepine in the elevated plus-maze: possible role of adenosine. Psychopharmacology (Berlin). 106:1992;85-89.